Want to see GYRE full AI Analyst Report?
GYRE Stock Chart & Stats
$6.65
-$0.07(-1.16%)
At close: 4:00 PM EDT
$6.65
-$0.07(-1.16%)
Day’s Range― - ―
52-Week Range$5.44 - $9.42
Previous Close$5.94
Volume33.77K
Average Volume (3M)51.39K
Market Cap
$682.86M
Enterprise Value$648.81
Total Cash (Recent Filing)$74.80M
Total Debt (Recent Filing)$3.42M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding106,033,760
10 Day Avg. Volume48,056
30 Day Avg. Volume51,389
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)5.95
Price to Sales (P/S)5.41
P/FCF Ratio-3.50K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.00Price Target Upside185.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$102.30M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizable equity base provide financial flexibility to fund clinical development and absorb volatility. This reduces refinancing risk while the company advances its commercial and pipeline assets.
High Gross ProfitabilityA very high gross margin indicates substantial product-level economics and provides room to support research, regulatory work and commercialization. Maintaining this profile could strengthen the funding capacity of the operating model.
China-Funded Global PipelineUsing established China revenue to finance selected global R&D can reduce dependence on external capital and improve development resilience. The approach also diversifies future growth across fibrosis, oncology and inflammatory disease programs.
Bears Say
Return To TTM LossesThe shift back to losses indicates that operating expenses are currently absorbing the benefit of strong gross profitability. Persistent earnings volatility could constrain internally funded investment and make future results less predictable.
Unreliable Operating Cash ConversionNegative TTM operating cash flow means reported product economics have not yet translated consistently into cash from operations. Uneven conversion increases reliance on balance-sheet resources and raises execution risk during pipeline expansion.
Generic Competition And Pipeline ExecutionGeneric pressure could limit the durability of established pirfenidone-related commercial growth and increase the need for successful line extensions. At the same time, a broad development portfolio creates substantial execution demands across indications and regions.
Gyre Therapeutics News
GYRE FAQ
What was Gyre Therapeutics’s price range in the past 12 months?
Gyre Therapeutics lowest stock price was $5.44 and its highest was $9.42 in the past 12 months.
What is Gyre Therapeutics’s market cap?
Gyre Therapeutics’s market cap is $682.86M.
When is Gyre Therapeutics’s upcoming earnings report date?
Gyre Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 74 days.
How were Gyre Therapeutics’s earnings last quarter?
Gyre Therapeutics released its earnings results on Aug 07, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.057 by -$0.063.
Is Gyre Therapeutics overvalued?
According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued.
Does Gyre Therapeutics pay dividends?
Gyre Therapeutics pays a Quarterly dividend of $3.6 which represents an annual dividend yield of N/A. See more information on Gyre Therapeutics dividends here
What is Gyre Therapeutics’s EPS estimate?
Gyre Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Gyre Therapeutics have?
Gyre Therapeutics has 106,033,760 shares outstanding.
What happened to Gyre Therapeutics’s price movement after its last earnings report?
Gyre Therapeutics reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.057. Following the earnings report the stock price went up 4.219%.
Which hedge fund is a major shareholder of Gyre Therapeutics?
Currently, no hedge funds are holding shares in GYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gyre Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (185.71% Upside)
$19.00 (185.71% Upside)
Insider Transactions
Sold Shares
Worth $433.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Gyre Therapeutics
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
GYRE Stock 12 Month Forecast
Average Price Target
$19.00
▲(185.71% Upside)
Technical Analysis
Ownership Overview
63.46% Insiders
1.46% Mutual Funds
4.45% Other Institutional Investors
28.99% Public Companies and
Individual Investors